An important side effect of dopamine agonists: Lung fibrosis

Benbir G., Demirkok S. S., Ertan S.

EURASIAN JOURNAL OF PULMONOLOGY, cilt.10, sa.2, ss.147-152, 2008 (ESCI, TRDizin) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 10 Sayı: 2
  • Basım Tarihi: 2008
  • Dergi Adı: EURASIAN JOURNAL OF PULMONOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.147-152
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Dopamine agonists, particularly ergot preperations, are related to pulmonary or retroperitoneal fibrosis, or cardiac valvular diseases. Several hypotheses have been suggested to explain the pathophysiological mechanism, including toxic fibrogenesis, vascular theory, and immunological theory. The fibrotic disease is said to be often reversible if the drug is stopped quickly. Follow-up in patients treated with ergot-dopamin agonists is therefore important by monitoring the related symptoms, and regular screening tests.